Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Mary Y Hu & Mark A Peppercorn. (2008) MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis. Expert Opinion on Pharmacotherapy 9:6, pages 1049-1058.
Read now
Read now
Alan C Moss & Mark A Peppercorn. (2007) The risks and the benefits of mesalazine as a treatment for ulcerative colitis. Expert Opinion on Drug Safety 6:2, pages 99-107.
Read now
Read now
Articles from other publishers (25)
T. Kucharzik, A. Dignass, R. Atreya, B. Bokemeyer, P. Esters, K. Herrlinger, K. Kannengiesser, P. Kienle, J. Langhorst, A. Lügering, S. Schreiber, A. Stallmach, J. Stein, A. Sturm, N. Teich & B. Siegmund. (2023) Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.1) – Februar 2023 – AWMF-Registriernummer: 021-009. Zeitschrift für Gastroenterologie 61:08, pages 1046-1134.
Crossref
Crossref
Huanhuan Zhu, Shaopeng Tong, Yan Cui, Xiaodong Wang & Minying Wang. (2021)
Tanshinol alleviates ulcerative colitis by promoting the expression of
VLDLR
. Drug Development Research 82:8, pages 1258-1268.
Crossref
Crossref
Torsten Kucharzik, Axel U. Dignass, Raja Atreya, Bernd Bokemeyer, Philip Esters, Klaus Herrlinger, Klaus Kannengießer, Peter Kienle, Jost Langhorst, Andreas Lügering, Stefan Schreiber, Andreas Stallmach, Jürgen Stein, Andreas Sturm, Niels Teich & Britta Siegmund. (2020) Aktualisierte S3-Leitlinie Colitis ulcerosa – Living Guideline. Zeitschrift für Gastroenterologie 58:12, pages e241-e326.
Crossref
Crossref
Richa Chibbar & Alan C. Moss. (2020) Mesalamine in the Initial Therapy of Ulcerative Colitis. Gastroenterology Clinics of North America 49:4, pages 689-704.
Crossref
Crossref
Thomas P. Chapman, Catarina Frias Gomes, Edouard Louis, Jean-Frédéric Colombel & Jack Satsangi. (2020) Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 52:1, pages 73-84.
Crossref
Crossref
Caroline Baehler, Beat Brüngger, Eva Blozik, Stephan R. Vavricka & Alain M. Schoepfer. (2019) Real-World Data on Topical Therapies and Annual Health Resource Utilization in Hospitalized Swiss Patients with Ulcerative Colitis. Inflammatory Intestinal Diseases 4:4, pages 144-153.
Crossref
Crossref
Reena Khanna & John K. Marshall. 2017. Crohn's Disease and Ulcerative Colitis. Crohn's Disease and Ulcerative Colitis
389
397
.
Hanan M. El-Gowelli, Evan I. Saad, Abdel-Galil A. Abdel-Galil & Einas R. Ibrahim. (2015) Co-administration of α-lipoic acid and cyclosporine aggravates colon ulceration of acetic acid-induced ulcerative colitis via facilitation of NO/COX-2/miR-210 cascade. Toxicology and Applied Pharmacology 288:3, pages 300-312.
Crossref
Crossref
Christopher S.J. Probert, Axel U. Dignass, Stefan Lindgren, Marco Oudkerk Pool & Philippe Marteau. (2014) Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: Rapid symptom resolution and improvements in quality of life. Journal of Crohn's and Colitis 8:3, pages 200-207.
Crossref
Crossref
F. Seibold, N. Fournier, C. Beglinger, C. Mottet, V. Pittet & G. Rogler. (2014) Topical therapy is underused in patients with ulcerative colitis. Journal of Crohn's and Colitis 8:1, pages 56-63.
Crossref
Crossref
Bella Zeisler, Trudy Lerer, James Markowitz, David Mack, Anne Griffiths, Athos Bousvaros, David Keljo, Joel Rosh, Jonathan Evans, Michael Kappelman, Anthony Otley, Marsha Kay, Andrew Grossman, Shehzad Saeed, Ryan Carvalho, Maria Oliva-Hemker, William Faubion, Boris Sudel, Marian Pfefferkorn, Farhat Ashai-Khan, Neal LeLeiko & Jeffrey Hyams. (2013) Outcome Following Aminosalicylate Therapy in Children Newly Diagnosed As Having Ulcerative Colitis. Journal of Pediatric Gastroenterology & Nutrition 56:1, pages 12-18.
Crossref
Crossref
John K Marshall, Marroon Thabane, A Hillary Steinhart, Jamie R Newman, Anju Anand & E Jan Irvine. (2012) Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Reena Khanna & John K. Marshall. 2012. Crohn's Disease and Ulcerative Colitis. Crohn's Disease and Ulcerative Colitis
453
466
.
Mark Lamet. (2010) A Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Mesalamine Suppositories 1 g at Bedtime and 500 mg Twice Daily in Patients with Active Mild-to-Moderate Ulcerative Proctitis. Digestive Diseases and Sciences 56:2, pages 513-522.
Crossref
Crossref
Pia Munkholm, Pierre Michetti, Chris S. Probert, Margarita Elkjaer & Philippe Marteau. (2010) Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine. European Journal of Gastroenterology & Hepatology 22:8, pages 912-916.
Crossref
Crossref
M.T. Pimpo, B. Galletti, G. Palumbo, A. Viscido, P. Gentile, R. Caprilli & G. Frieri. (2010) Mesalazine vanishing time from rectal mucosa following its topical administration. Journal of Crohn's and Colitis 4:1, pages 102-105.
Crossref
Crossref
Siew C. Ng & Michael A. Kamm. (2009) Therapeutic strategies for the management of ulcerative colitis. Inflammatory Bowel Diseases 15:6, pages 935-950.
Crossref
Crossref
William N. Tindall. (2009) New approaches to adherence issues when dosing oral aminosalicylates in ulcerative colitis. American Journal of Health-System Pharmacy 66:5, pages 451-457.
Crossref
Crossref
Javier P. Gisbert & Fernando Gomollón. (2007) Errores frecuentes en el manejo del paciente ambulatorio con enfermedad inflamatoria intestinal. Gastroenterología y Hepatología 30:8, pages 469-486.
Crossref
Crossref
László Lakatos & Péter László Lakatos. (2007) Medical therapy of inflammatory bowel diseases: Ulcerative colitis. Orvosi Hetilap 148:25, pages 1163-1170.
Crossref
Crossref
T. ORCHARD, C. S. PROBERT & S. KESHAV. (2006) Review article: maintenance therapy in patients with ulcerative colitis. Alimentary Pharmacology and Therapeutics 24:s1, pages 17-22.
Crossref
Crossref
Alan C Moss, Adam S Cheifetz & Mark A Peppercorn. (2006) Combined oral and topical mesalazine treatment for extensive ulcerative colitis. Nature Clinical Practice Gastroenterology & Hepatology 3:5, pages 290-293.
Crossref
Crossref
S. V. KANE. (2006) Systematic review: adherence issues in the treatment of ulcerative colitis. Alimentary Pharmacology and Therapeutics 23:5, pages 577-585.
Crossref
Crossref
G.R. Lichtenstein. (2006) Combined Oral and Enema Treatment With Pentasa (Mesalazine) Is Superior to Oral Therapy Alone in Patients With Extensive Mild/Moderate Active Ulcerative Colitis: A Randomised, Double Blind, Placebo Controlled Study. Yearbook of Gastroenterology 2006, pages 113-116.
Crossref
Crossref
Qi-Kui Chen. (2005) Characteristics and therapeutic efficacy of sulfasalazine in patients with mildly and moderately active ulcerative colitis. World Journal of Gastroenterology 11:16, pages 2462.
Crossref
Crossref